Clinical trial · Interventional
EUS Guided HVA and PVA for Circulating Tumor DNA in Patients
Endoscopic Ultrasound Guided Hepatic and Portal Vein Aspiration for Circulating Tumor DNA in Patients Suffering From GI Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of technologies for ctDNA analysis have presented an attractive opportunity for minimally invasive "liquid biopsy" genomic diagnostics. The investigators plan to perform EUS-guided portal vein and hepatic vein aspiration in GI cancers patients. The aim of the current study is thus to examine the concentration of ctDNA in portal vein (EUS-guided PVA), hepatic vein (EUS-guided HVA) and peripheral blood to understand the first pass effect of the liver with gastrointestinal (GI) cancers, and the possibility of using ctDNA as a marker for preoperative staging, restaging after neoadjuvant chemotherapy, and monitoring for recurrence.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor Cell | — | UNRESOLVED | — |
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EUS-guided portal vein and hepatic vein aspiration | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- EUS-guided PVA and HVA
- description
- Patient will undergo EUS-guided PVA and HVA
- interventionNames
- Diagnostic Test: EUS-guided portal vein and hepatic vein aspiration
Primary outcomes (1)
- measure
- Variant allelic fraction (expressed in %) of serum ctDNA from HVB, PVB and peripheral blood
- timeFrame
- 3 months
- description
- Plasma DNA will be extracted using the QIAamp Circulating Nucleic Acid Kit (Qiagen), and the concentration of the circulating tumor DNA will be reported in variant allelic fraction (expressed in %)
Secondary outcomes (7)
- measure
- Variant allelic fraction (expressed in %) of Genomic and proteomic analysis of ctDNA
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion criteria:
1. Age \>= 18 years old
2. Newly diagnosed stage II-IV distal gastric cancer, pancreatic cancer or colorectal cancer
3. Undergoing treatment with either:
1. Surgery
2. Neoadjuvant chemotherapy
3. Neoadjuvant chemoirradiation
4. Palliative chemotherapy/ immunotherapy
Exclusion criteria:
<!-- -->
1. Synchronous cancer of other sites
2. Cardia, high lesser curve tumors, oesophagogastric junction tumors
3. Presence of bulky lymph nodes at lesser curve/ coeliac region precluding a clear EUS puncture site to portal vein and hepatic vein
4. Patients with coagulopathy (international normalized ratio \>1.3, partial thromboplastin time greater than twice that of control), platelet count \<50,000x103/uL
5. Patients unwilling to undergo follow-up assessments
6. Patients with liver cirrhosis, portal hypertension and/ or gastric varices
7. Patient refusal to participate
\-References
Publications (0)
Data not yet available